Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Optimizing CNS prophylaxis in the treatment of ALL

Martin Schrappe • 8 Dec 2023
ASH 2023
Acute Lymphoblastic Leukemia Leukemia

Martin Schrappe, MD, University Medical Center Schleswig-Holstein, Kiel, Germany, explores optimal methods for CNS prophylaxis when treating acute lymphoblastic leukemia (ALL). Dr Schrappe highlights the importance of considering the subtype of ALL when choosing between cranial radiotherapy and intrathecal chemotherapy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Martin Schrappe

1:24
Immunotherapy with blinatumomab vs chemotherapy in pediatric patients with newly diagnosed B-ALL
Martin Schrappe • 8 Dec 2023
2:15
Subtypes of pediatric acute lymphoblastic leukemia
Martin Schrappe • 25 Feb 2016
1:40
Identifying patients at different risk of relapse in childhood acute lymphoblastic leukemia (ALL)
Martin Schrappe • 2 Dec 2016

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals